Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.49 |
| ▸ | HTR6 | P50406 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3321494 | 0.85 | MAOB (0.65) | MAOBCYP1A2CYP3A4CYP2D6MAPT | |
| SCHEMBL24686580 | 0.83 | MAOB (0.56) | MAOBIDO1AGXTSLC6A4 | |
| SCHEMBL2877893 | 0.83 | RAB9A (0.56) | MAOBMAPTF2 | |
| SCHEMBL29514868 | 0.82 | MAOB (0.61) | MAOBIDO1AGXT | |
| SCHEMBL1406384 | 0.82 | MAOB (0.61) | MAOBCYP1A2CYP3A4CYP2D6MAPT | |
| SCHEMBL156718 | 0.82 | MAOB (0.61) | MAOBIDO1AGXT | |
| SCHEMBL29388015 | 0.82 | MAOB (0.61) | MAOBIDO1AGXT | |
| Hydrochloric Acid SCHEMBL7983144 | 0.81 | RAB9A (0.55) | MAOBMAPTF2 | |
| SCHEMBL28337440 | 0.81 | MAOB (0.58) | MAOBCYP1A2CYP3A4CYP2D6MAPT | |
| Hydrochloric Acid SCHEMBL216004 | 0.81 | MAOB (0.62) | MAOBIDO1AGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150366868-A1 | CANCER TREATMENT METHOD | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| US-8987284-B2 | Phosphorus containing quinazoline compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-8444988-B2 | Cancer treatment method | GLAXOSMITHKLINE LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2012-08-02 | — | — | US | disclosed |
| EP-2448409-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | Newgen Therapeutics, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20120058113-A1 | CANCER TREATMENT METHOD | NOVARTIS AG (CH) | 2012-03-08 | — | — | US | disclosed |
| US-20110312982-A1 | Cancer Treatment Method | NOVARTIS AG (CH) | 2011-12-22 | — | — | US | disclosed |
| WO-2011002523-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | KANIONUSA INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20100249160-A1 | Cancer Treatment Method | LEO OSPREY LIMITED (GB) | 2010-09-30 | — | — | US | disclosed |
| US-20100010022-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM CORPORATION (US) | 2010-01-14 | — | — | US | disclosed |
| US-20050143401-A1 | Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine | COCKERILL GEORGE S (GB) | 2005-06-30 | — | — | US | disclosed |
| EP-1353693-B1 | PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINEAMINE AND PACLITAXEL, CARBOPLATIN OR VINORELBINE FOR THE TREATMENT OF CANCER | GLAXO GROUP LTD (GB) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512413-A2 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| WO-2004112714-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| EP-1488809-A1 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-20040053946-A1 | Cancer treatment method | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1353693-A2 | PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINEAMINE AND ANOTHER ANTI-NEOPLASTIC AGENT FOR THE TREATMENT OF CANCER | GLAXO GROUP LIMITED (GB) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002056912-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER CONTAINING A 4-QUINAZOLINEAMINE AND ANOTHER ANTI-NEOPLASTIC AGENT | GLAXO GROUP LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| EP-1192151-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001004111-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010022-A1 | CANCER TREATMENT METHOD | TP53, TYMP, TOP2A | MAOB 1253/4885CYP1A2 364/4885CYP3A4 132/4885 |
| US-20120058113-A1 | CANCER TREATMENT METHOD | TP53, HNMT, TOP2B | MAOB 923/4885CYP1A2 639/4885CYP3A4 308/4885 |
| US-20110312982-A1 | Cancer Treatment Method | HNMT, TP53, TUBB4A | MAOB 856/4885CYP1A2 745/4885CYP3A4 291/4885 |
| US-20150366868-A1 | CANCER TREATMENT METHOD | TP53, HNMT, TOP2B | MAOB 923/4885CYP1A2 639/4885CYP3A4 308/4885 |
| US-20040053946-A1 | Cancer treatment method | TP53, HNMT, TOP2B | MAOB 923/4885CYP1A2 639/4885CYP3A4 308/4885 |
| US-20050143401-A1 | Anticancer agents; (4-(3-Fluorobenzyloxy)-3-chlorophenyl)-(6-(2-((2-methanesulphonyl-ethylamino)ethyl)-thiazol-4-yl)-quinazolin-4-yl)-amine | ABL1, ERBB2, ERBB4 | MAOB 1566/4885CYP1A2 2656/4885CYP3A4 1517/4885 |
| US-20100249160-A1 | Cancer Treatment Method | TP53, HNMT, TOP2B | MAOB 923/4885CYP1A2 639/4885CYP3A4 308/4885 |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | PPIP5K2, PIK3CA, PHKA1 | MAOB 4771/4885CYP1A2 4077/4885CYP3A4 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.